Email this article Analysis of the gene polymorphism of matrix metalloproteinase-2 and -9 in patients with coronary heart disease
- Authors: Shevchenko A.V.1, Golovanova O.V.1, Konenkov V.I.1, Tolkacheva O.M.1, Maksimov V.N.1, Voevoda M.I.1, Romashchenko A.G.1, Shevchenko AV2, Golovanova OV2, Konenkov VI2, Tolkacheva OM3, Maksimov VN4, Voyevoda MI4, Romashchenko AG5
-
Affiliations:
- Clinical Immunogenetics Laboratory, Research Institute of Clinical and Experimental Lymphology, Siberian Branch, Russian Academy of Medical Sciences
- Town Clinical Hospital Twenty-Nine
- Research Institute of Therapy, Siberian Branch, Russian Academy of Medical Sciences
- Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
- Issue: Vol 82, No 1 (2010)
- Pages: 31-34
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/33382
- ID: 33382
Cite item
Full Text
Abstract
Materials and methods. The influence of single nucleotide polymorphism in the promoter region of the gene of matrix metalloproteinase (MMP)-2 at position -1306 and that of MMP-9 at position -1562 on the development of complications was studied in 181 patients with atherosclerosis by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis of amplification products.
Results. A significant genotype increase with enhanced MMP-9 gene transcriptional activity was found in the patients aged 55 years inclusively who had been diagnosed as having myocardial infarction as compared with an older age group and, on the contrary, a rise in the MMP-2 genotype with a high promoter activity in the older age group.
Conclusion. The findings suggest that the functional polymorphism in the promoter region of the MMP-2 and MMP-9 genes plays a certain role in the development of acute coronary events.
About the authors
Alla Vladimirovna Shevchenko
Email: shalla64@mail.ru
Ol'ga Valer'evna Golovanova
Email: golovanova_olga@mail.ru
Vladimir Iosifovich Konenkov
Email: konen@soramn.ru
Ol'ga Mikhaylovna Tolkacheva
Email: tolkacheva-olga@mail.ru
Vladimir Nikolaevich Maksimov
Email: medik11@mail.ru
Mikhail Ivanovich Voevoda
Email: voevoda@iimed.ru
Aida Gerasimovna Romashchenko
Email: romasch@bionet.nsc.ru
A V Shevchenko
Clinical Immunogenetics Laboratory, Research Institute of Clinical and Experimental Lymphology, Siberian Branch, Russian Academy of Medical SciencesClinical Immunogenetics Laboratory, Research Institute of Clinical and Experimental Lymphology, Siberian Branch, Russian Academy of Medical Sciences
O V Golovanova
Clinical Immunogenetics Laboratory, Research Institute of Clinical and Experimental Lymphology, Siberian Branch, Russian Academy of Medical SciencesClinical Immunogenetics Laboratory, Research Institute of Clinical and Experimental Lymphology, Siberian Branch, Russian Academy of Medical Sciences
V I Konenkov
Clinical Immunogenetics Laboratory, Research Institute of Clinical and Experimental Lymphology, Siberian Branch, Russian Academy of Medical SciencesClinical Immunogenetics Laboratory, Research Institute of Clinical and Experimental Lymphology, Siberian Branch, Russian Academy of Medical Sciences
O M Tolkacheva
Town Clinical Hospital Twenty-NineTown Clinical Hospital Twenty-Nine
V N Maksimov
Research Institute of Therapy, Siberian Branch, Russian Academy of Medical SciencesResearch Institute of Therapy, Siberian Branch, Russian Academy of Medical Sciences
M I Voyevoda
Research Institute of Therapy, Siberian Branch, Russian Academy of Medical SciencesResearch Institute of Therapy, Siberian Branch, Russian Academy of Medical Sciences
A G Romashchenko
Institute of Cytology and Genetics, Siberian Branch, Russian Academy of SciencesInstitute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
References
- Панченко Е. П. Механизмы развития острого коронарного синдрома. Рус. мед. журн. 2000; 8: 359-370.
- Shah P. K., Falk E., Badimon J. J. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-1569.
- Козулин В. Ю. Российские рекомендации по лечению острого коронарного синдрома. http: //www.infarktu.net/catalog/professional/1/articles
- Wilhelm S. M., Collier I. E., Marmer B. L. et al. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 1989; 264: 17213-17221.
- Pollanen P. J., Karhunen P. J., Mikkelsson J. et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: An autopsy study. Arterioscler. Throm. Vasc. Biol. 2001; 21: 1446-1450.
- Королева О. С., Затейщиков Д. А. Биомаркеры в кардиологии: регистрация внутрисосудистого воспаления. Фарматека. Кардиол. и общ. тер. 2007; 8/9: 30-36.
- Inokubo Y., Hanada H. L. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J. 2001; 141: 211-217.
- Kondapaka S. B., Fridman R., Reddy K. B. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int. J. Cancer 1997; 70: 722-726.
- Zhang В., Herrmann S. M., Eriksson P. et al. Functional polymorphism in the regulatory region of gelatinase В gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-1794.
- Pollanen P. J., Lehtimaki Т., Mikkelsson J. et al. Matrix metalloproteinase 3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques. Atherosclerosis 2005; 180: 73-78.
- Lamblin N., Bauters Ch., Hermant X. et al. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J. Am. Coll. Cardiol. 2002; 40 (1): 43-48.
- Price S. J., Greaves D. R., Watkins H. Functional genetic variants of matrix metalloproteinases (NMPS). J. Biol. Chem. 2001; 276: 7549-7558.
- Okamoto К., Mimura К., Murawak Y., Yuasa I. Association of functional gene polymorphisms of matrix metalloproteinase MMP-1, MMP-3 and MMP-9 with the progression of chronic liver disease. J. Gastroenterol. Hepatol. 2005; 20 (7): 1102- 1108.
- Bland J. M., Altman D. G. Education and debate. The odds ratio. Br. Med. J. 2000; 320: 1468.
- Гончарова Н. С., Моисеева О. М., Шляхто Е. В., Алешина Г. М. Матриксные металлопротеиназы: значение в ремоделировании миокарда при клапанных пороках сердца. Кардиология 2007; 12: 49-52.
- Blankenberg S., Rupprecht H. J., Poirier O. et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-1585.
- Cho H.-J., Chae I.-H., Park K.-W. et al. Functional polymorphism in the promoter region of the gelatinase В gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J. Hum. Genet. 2002; 47 (2): 88-91.
- Morgan A. R., Zhang В., Tapper W. et al. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J. Mol. Med. 2003; 81 (5): 321-326.
- Haberbosch W., Gardemann A. Gelatinase В С (-1562) Т polymorphism in relation to ischaemic heart disease. Scand. J. Clin. Lab. Invest. 2005; 65: 513-522.
- Galis Z. S., Sukhova G. K., Kranzhofer R. et al. Macrophage foam cells from experimental atheroma constitutively produce matrix degrading proteinases. Proc Natl, Acad.Sci. USA 1995; 92: 402-406.
- Galis Z. S., Sukhova G. K., Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J. 1995; 9 (10): 974-980.
- Newby A. C., Johnson J. L. Genetic strategies to elucidate the roles of matrix Metalloproteinases in atherosclerotic plaque growth and stability. Circ. Res. 2005; 97: 958-960.
- Spinale F. G. Matrix metalloproteinase gene polymorphisms in heart failure: new pieces to the myocardial matrix puzzle. Eur. Heart J. 2004; 25: 631-633.
Supplementary files
